Clinical trials: Survival Rate
Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications)
HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer
This is single center prospective phase 2 randomized trial aiming to compare biochemical and clinical relapse free survival and toxicity profiles of stereotactic body radiotherapy (SBRT) versus high dose rate brachytherapy (HDRB)…
- Trial name
- NCT04870567
- Testing
- Stereotactic ablative radiotherapy, High dose rate brachytherapy
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Overall Survival Rates
Malignant Testicular Tumors in Children: A Single Institution's 12-year Experience
Background and Objectives. Testicular neoplasms are not commonly found in children, a formidable threat if treated inappropriately. However, there is no consensus concerning their management.
- Trial name
- NCT04826952
- Testing
- Orchiectomy
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Chang Gung Memorial Hospital
Disease-free Survival Rate
Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma
To see the effect if a combination of neoadjuvant chemotherapy combined with Camrelizumab followed by chemoradiotherapy in treating patients without distant metastasis nasopharyngeal carcinoma
- Trial name
- NCT04782765
- Testing
- Camrelizumab+Chemotherapy+Chemoradiotherapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Recurrent Cervical Carcinoma, Radiotherapy
Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
Patients with recurrent or metastatic uterine cervical squamous carcinoma have very poor prognosis. For eligible patients, radiotherapy remains the choice, which has the most effective impact on the survival periods.
- Conditions
- Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor, Nimotuzumab
- Trial name
- NCT04664244
- Testing
- Combination of nimotuzumab and radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Lei Li
Success, Survival Rate
Prospective Clinical Trial of Onlay-carrying Patients
A record of the type of onlay will be made with respect to its extension, tooth or teeth to be treated, the material of clothing and the substrate on which the adhesion and cementing method, as well as the type of antagonist.
- Conditions
- Success, Survival Rate, Clinical Performance
- Trial name
- NCT04396080
- Testing
- Partial restoration in posterior teeth
- Where
- Spain
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Valencia
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
Outcomes, Survival Rates
The Chimerix CMX001 Registry
The prospective observational study is to establish a registry database to evaluate the potential impact of prior treatment with CMX001 on the long-term incidence of specific events, such as outcomes, late CMV and other…
- Trial name
- CMX001 (NCT02167685)
- Testing
- CMX001
- Where
- 51 sites in United States, Belgium and 1 more
- Volunteers
- 550 people
- Sponsor
- Jazz Pharmaceuticals
Tumor Response Rate, Overall Survival
TILA-TACE in Treatment of Hepatocellular Carcinoma
To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate.
- Trial name
- NCT03910140
- Testing
- TILA-TACE treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Aspirin as an Adjuvant Therapy, to Observe Its Effect on the Disease Free Survival Rate of Patients With Esophageal Squamous Cell Carcinoma
Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma
Esophageal cancers are the seventh most common cancer in the world and one of the most common causes of cancer deaths. In some parts of China, the incidence of SCC is among the highest in the world.
- Trial name
- NCT03900871
- Testing
- Acetylsalicylic acid
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Hebei Medical University Fourth Hospital
Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety
Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial
Gastric cancer is the one of the leading cause of cancer death in the worldwide. Gastric cancer originates from the most superficial mucosal epithelial cells of the stomach wall, which can occur in various parts of the stomach…
- Trial name
- NCT03531931
- Testing
- Apatinib/Capecitatine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Carcinoma, Hepatocellular, Survival Rate
Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor
This clinical trial aims to compare hepatectomy with Transarterial Chemoembolization (TACE) for Hepatic Cellular Cancer With Solitary Huge Tumor (≥5cm).
- Trial name
- NCT03191123
- Testing
- hepatic resection, TACE
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huazhong University of Science and Technology
Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Epigenetic Biomarker for Osteosarcoma
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down…
- Conditions
- Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR, Progression-free Survival, PFS, Overall Survival, OS
- Trial name
- NCT03336554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Colorectal Cancer Metastatic, Survival Rate
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved
The body immunity is important to the development of tumor. The immune system is in charge of monitoring and cleaning tumor cells in circulation. Anesthesia may alter the immune response and affect the elimination of tumor cells.
- Conditions
- Colorectal Cancer Metastatic, Survival Rate, General Anesthetics Toxicity, Lymphocyte Destruction
- Trial name
- NCT03193710
- Testing
- Propofol, Sevoflurane, Remifentanil
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Guizhi Du
Survival Rate
Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer
Locally advance breast cancer and extensive locoregional recurrence are still considered as complexity of reconstruction. Although previous studies concluded that omental transposition was considerably indicated in poor…
- Trial name
- NCT03052621
- Testing
- Omental transposition
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Queen Sirikit Centre for Breast Cancer
Sedentary Lifestyle, Breast Neoplasms
Step by Step: A Tailored Walking Intervention for Breast Cancer Survivors
This study aims to recruit post-treatment breast cancer survivors for a 12-week 2-arm randomized walking intervention. All intervention materials will be delivered electronically.
- Conditions
- Sedentary Lifestyle, Breast Neoplasms, Survival Rate (Survivorship)
- Trial name
- NCT01845519
- Testing
- Tailored Email, Targeted Email
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Leanne Kaye
Aesthetic Evaluation, Implant Survival Rate
Aesthetic Evaluation of Different Abutment Materials for OsseoSpeed Implants
The objective of the study was to assess the aesthetic outcome of different abutments materials and shapes on dental implants . A set of parameters, including assessments of the mucosa and periodontal tissue , soft tissue …
- Trial name
- NCT02090647
- Testing
- aesthetic outcome
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Siena
Rectal Cancer, Treatment
Safety and Efficacy Study of Cylindrical Abdominoperineal Resection to Treat Rectal Cancer
The purpose of this study is to determine whether cylindrical abdominoperineal resection is effective in the treatment of advanced very low rectal cancer
- Conditions
- Rectal Cancer, Treatment, Postoperative Complications, Neoplasm Recurrence, Local
- Trial name
- NCT00949273
- Testing
- cylindrical abdominoperineal resection
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Beijing Chao Yang Hospital
Prostatic Neoplasms, Neoplasms, Hormone-Dependent
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are…
- Conditions
- Prostatic Neoplasms, Neoplasms, Hormone-Dependent, Tumor Markers, Biological, Survival Rate
- Trial name
- PROSUT (NCT00748358)
- Testing
- sunitinib
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bone-to-implant Contact, Success Rate
Randomized Controlled Trial of Full-Arch Rehabilitation
This clinical study has the objective to compare the radiographic evaluations after 3 years of follow-up of immediate loaded implant-prosthetic rehabilitation, carried out randomly using the methodology for computer guided…
- Conditions
- Bone-to-implant Contact, Success Rate, Survival Rate
- Trial name
- NCT01905306
- Testing
- computer guided implant planning, free hand implants placement
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Siena
Progress-free Survival, Overall Response Rate
Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China.
- Conditions
- Progress-free Survival, Overall Response Rate, Adverse Events
- Trial name
- HOPES (NCT01291667)
- Volunteers
- 330 people
- Sponsor
- Shanghai CP Guojian Pharmaceutical Co., Ltd.